July 2, 2021Multiple Sclerosis JournalOpen Access

Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry

View Full Paper

Ask AI

Bookmark

Abstract

Rituximab treatment, known to increase the risk of severe infections in general, also confers such a risk for MS patients with COVID-19, in comparison with other MS DMTs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Spelman et al. (2021) studied this question.

synapsesocial.com/papers/69dd5a248557d5ab8f40d1f9 https://doi.org/10.1177/13524585211026272

View Full Paper

Ask AI

Bookmark

Abstract

Rituximab treatment, known to increase the risk of severe infections in general, also confers such a risk for MS patients with COVID-19, in comparison with other MS DMTs.